The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1286
May 19, 2008
View Complete Issue         Table of Contents 2019 
Pharmacogenetic-Based Dosing of Warfarin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pharmacogenetic-Based Dosing of Warfarin
May 19, 2008 (Issue: 1286)
Warfarin sodium (Coumadin, and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for single nucleotide polymorphisms (SNPs) that...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pharmacogenetic-Based Dosing of Warfarin
Article code: 1286b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.